Skip to the observation
Medicinal BPC

BPC-157 dosage numbers belong to their studies.

A dose written down can seem more settled than the evidence behind it. Here, the people, the route and the purpose of the study matter more than the number on its own.

An adult’s bare inner elbow and forearm reaching to draw a curtain
An inner elbow and forearm in morning light, reaching for a curtain.

What the small human study used

In the 2025 infusion pilot, two adults received 10 mg of BPC-157 on the first study day and 20 mg on the second. It went into a vein. Those are experimental amounts, not amounts to copy.

The researchers checked short-term safety, not whether an injury healed. The two participants had used BPC-157 infusions before, and their results can’t settle a treatment range. BPC-157 has no FDA-approved label supplying an amount for a particular condition either.

Animal papers often give amounts based on body weight. I leave those figures in their experiments. Calculating a human number wouldn’t supply the missing evidence about whether that amount helps a person.

How it enters the body matters

A study in rats and dogs found rapid breakdown of BPC-157. That describes what happened in those animals. It doesn’t tell us how often a person would need a dose, or whether it would help.

The FDA review found no human absorption data for pills, shots under the skin, nasal sprays or skin preparations. It separately records enema studies in which BPC-157 wasn’t detected in blood.

These routes aren’t interchangeable versions of a settled treatment. A result from one can’t fill the gaps for another. Knowing that BPC-157 disappears quickly in an animal doesn’t tell us when to repeat it in a person.

A prescription is a separate decision

“Current as of” reads April 22, 2026 on the FDA listing, where BPC-157’s nomination is marked withdrawn. Taking back a nomination grants no permission to compound the substance. A prescription doesn’t establish that it repairs human injuries.

What supports the proposed use? What’s known about the preparation, and how would problems be monitored? Those are questions for a clinician. The reason, amount and route belong in that conversation, not a regimen from this page.

The numbers
Amounts in one small study do not define a human treatment range.
The decision
A provider’s review is separate from FDA approval and proof of benefit. The decision on a BPC-157 prescription belongs to the licensed U.S. clinician assessing the person through Promise Peptides (mypromise.com); that assessment can end in a refusal of care. This route serves U.S. patients only, and not everyone qualifies; a compounded medicine has no FDA approval.

Read what remains unknown about safety